Home > PE Ratio > BETA DRUGS

BETA DRUGS
PE (Price/Earnings) Ratio

The Current P/E Ratio of BETA DRUGS is 69.60.

Share Price ₹2,229.1Jul 17,2026
Market Cap ₹2,474.3 Cr
Earnings-TTM₹35.5 CrTTM-Consolidated Results
Price/Earnings69.60xCalculated as Market Cap/Earnings
Explore Stock Analytics
COMMUNITY POLL
for BETA DRUGS
Please provide your vote to see the results
BETA DRUGS is part of below Screeners ↓
Top Small Cap Stocks with Best Fundamentals
Best Quarterly Growth Small Cap Stocks
Best 1M Momentum Small Cap Stocks

Definition & Calculation of PE (Price/Earnings) ratio of BETA DRUGS

Price-to-Earnings ratio, P/E Multiple, or P/E Ratio is an important valuation multiple that is defined as:

P/E = Market Capitalization / Net Income

or, using per-share numbers:

P/E = Stock Price / Earnings Per Share (EPS)

Applying the above formula, P/E ratio of BETA DRUGS is calculated as :

Current Market Cap [ ₹2,474.3 Cr] as on Jul 17,2026

(/) Earnings [ ₹35.5 Cr] based on TTM-Consolidated Results

(=) P/E Ratio [ 69.60x ]

P/E Ratio indicates the multiple of earnings investors are willing to pay to own one share of the company.

Thus, for BETA DRUGS , the investors are currently willing to pay 69.60 times earnings to own 1 share of the company.

PE Multiples are the most widely used valuation multiple in practice.

Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.

In such cases, you may consider using Price to Book ratio or Price to Sales ratio of BETA DRUGS !

P/E ratios, also, would not adjust for differences in the capital structure between companies.

The chart below summarizes the trend in P/E Ratio of BETA DRUGS over the last five years.

Historical PE (Price/Earnings) ratio chart of BETA DRUGS


PE Ratio Performance Analysis for BETA DRUGS

- BETA DRUGS 's latest p/e ratio is 69.60x.

- BETA DRUGS 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 25.54x.

- BETA DRUGS 's operated at median p/e ratio of 21.9x from fiscal years ending March 2018 to 2022.

- Looking back at the last 5 fiscal years, BETA DRUGS 's p/e ratio peaked in Mar2025 at 45.35x.

- BETA DRUGS 's p/e ratio hit its five-year low in Mar2021 of 9.84x.


How does BETA DRUGS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?

Peer Comparison (Pharmaceuticals & Drugs Industry)Earnings-TTM (Cr)PE RatioMarket Cap
BETA DRUGS 35.5569.602,474.3
SUN PHARMACEUTICAL INDUSTRIES LTD11,564.5040.11463,815.0
DIVIS LABORATORIES LTD2,568.0075.03192,678.0
TORRENT PHARMACEUTICALS LTD2,138.0075.46161,323.0
CIPLA LTD3,869.7929.61114,585.0
DR REDDYS LABORATORIES LTD4,144.2024.39101,067.0
MANKIND PHARMA LTD1,926.4153.41102,896.0
LUPIN LTD5,355.4720.85111,661.0
ZYDUS LIFESCIENCES LTD5,026.4022.68113,990.0
AUROBINDO PHARMA LTD3,501.4525.2188,265.9
LAURUS LABS LTD889.8592.8782,639.3

Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs BETA DRUGS 's P/E Ratio

Top 10 Industry PeersPE Ratio
Min industry PE 20.85x
Max industry PE 92.87x
Median industry PE 40.11x
Average industry PE 48.11x



You may also like the below Video Courses